Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | F12 | P00748 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.48 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL259335 | 0.77 | ALDH1A1 (0.53) | ALDH1A1HPGDTP53POLBKMT2A | |
| SCHEMBL30794794 | 0.73 | KMT2A (0.50) | TP53POLBKMT2ALMNAMEN1 | |
| SCHEMBL4565977 | 0.73 | MEN1 (0.49) | HPGDTP53POLBKMT2ALMNA | |
| SCHEMBL4586310 | 0.72 | TSHR (0.60) | HPGDPOLBKMT2ALMNAMEN1 | |
| SCHEMBL4039962 | 0.72 | KMT2A (0.58) | POLBKMT2ALMNAMEN1PKM | |
| SCHEMBL1437928 | 0.71 | KMT2A (0.80) | HPGDKMT2ALMNAMEN1MAPT | |
| SCHEMBL18493208 | 0.71 | KCNK3 (0.60) | POLBKMT2AMEN1MAPTKCNK3 | |
| SCHEMBL22085391 | 0.71 | KMT2A (0.59) | TP53KMT2ALMNAMEN1KCNK3 | |
| SCHEMBL4138460 | 0.71 | POLB (0.67) | HPGDPOLBKMT2ALMNAMEN1 | |
| SCHEMBL7363838 | 0.71 | KMT2A (0.59) | ALDH1A1HPGDKMT2ALMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040048889-A1 | Use of non-competitive and selective glur5 antagonists as gultamate receptor modulating compounds | NEUROSEARCH A/S (DK) | 2004-03-11 | — | — | US | claimed |
| EP-1355640-A1 | USE OF NON-COMPETITIVE AND SELECTIVE GLUR5 ANTAGONISTS AS GLUTAMATE RECEPTOR MODULATING COMPOUNDS | NEUROSEARCH A/S (DK) | 2003-10-29 | — | — | EP | claimed |
| WO-2002058691-A1 | USE OF NON-COMPETITIVE AND SELECTIVE GLUR5 ANTAGONISTS AS GLUTAMATE RECEPTOR MODULATING COMPOUNDS | NEUROSEARCH A/S (DK) | 2002-08-01 | — | — | WO | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| US-7488756-B2 | Use of non-competitive and selective GluR5 antagonists as glutamate receptor modulating compounds | NEUROSEARCH A/S (DK) | 2009-02-10 | — | — | US | disclosed |
| US-20040048889-A1 | Use of non-competitive and selective glur5 antagonists as gultamate receptor modulating compounds | NEUROSEARCH A/S (DK) | 2004-03-11 | — | — | US | disclosed |
| EP-1355640-A1 | USE OF NON-COMPETITIVE AND SELECTIVE GLUR5 ANTAGONISTS AS GLUTAMATE RECEPTOR MODULATING COMPOUNDS | NEUROSEARCH A/S (DK) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002058691-A1 | USE OF NON-COMPETITIVE AND SELECTIVE GLUR5 ANTAGONISTS AS GLUTAMATE RECEPTOR MODULATING COMPOUNDS | NEUROSEARCH A/S (DK) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048889-A1 | Use of non-competitive and selective glur5 antagonists as gultamate receptor modulating compounds | GRM5, GRIK5, GRIN1 | ALDH1A1 2864/4885HPGD 1265/4885TP53 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.